Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Ltd."

526 News Found

Alkem launches Kojiglo serum to manage facial hyperpigmentation
News | February 05, 2025

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology


Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


Merck inaugurates expansion of its Peenya facility in Bengaluru
News | January 25, 2025

Merck inaugurates expansion of its Peenya facility in Bengaluru

Expansion makes Merck Life Science in Bengaluru a key manufacturing location in the APAC region


Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
News | January 24, 2025

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase


Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
News | January 23, 2025

Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr

The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY


Bajaj Healthcare receives exclusive rights for manufacturing, distribution & sales of finished formulation of Magnesium L Threonate
News | January 17, 2025

Bajaj Healthcare receives exclusive rights for manufacturing, distribution & sales of finished formulation of Magnesium L Threonate

The brand Magtein by Threotech has a sales value of approximately US $438 million


Alembic announces USFDA final approval for Brexpiprazole Tablets
Drug Approval | January 16, 2025

Alembic announces USFDA final approval for Brexpiprazole Tablets

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets


Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical
News | January 09, 2025

Mitsubishi Tanabe Pharma enters into a sub-licensing agreement for oral spleen tyrosine inhibitor fostamatinib in Taiwan with Kissei Pharmaceutical

This product is an oral SYK inhibitor and suppresses platelet destruction by macrophages and platelet depletion